Core Insights - The article highlights a landmark meeting co-sponsored by LIXTE Biotechnology Holdings, focusing on the activation of oncogenic signaling as a novel cancer treatment strategy [1][2] - LIXTE's lead compound, LB-100, was presented as a first-in-class PP2A inhibitor that activates oncogenic signaling, leading to cancer cell toxicity [2][4] Group 1: Conference Highlights - The conference introduced a paradigm shift in cancer therapy, advocating for the activation of oncogenic pathways rather than solely inhibiting them [3] - LB-100 exemplifies this approach by inhibiting PP2A, which removes a cellular "off switch," resulting in uncontrolled signaling that drives cancer cells to self-destruction [4] - Presentations at the conference reinforced the recognition of PP2A inhibition as a new therapeutic frontier, supporting LB-100's role as a platform therapy [5] Group 2: Company Positioning - By co-sponsoring the meeting, LIXTE positioned itself as a global thought leader in innovative cancer therapies, demonstrating its commitment to advancing cancer research [6] - LIXTE is focused on developing therapies targeting the PP2A pathway, with LB-100 showing strong preclinical results and early-stage clinical tolerability [7] - The company is currently advancing a proof-of-concept trial in Ovarian Clear Cell Carcinoma, indicating its active role in clinical development [7]

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences. Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NYManagement is scheduled to participate in a fireside chat on Monday, September 8h at 10:50 a.m. Pacific Time / 1:50 p.m. Eastern Time. Q3 Investor Summit Group Virtual ConferenceManag ...

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a ...

Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with I ...

Company Overview - Minovia Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for mitochondrial diseases and age-related decline [1][5] - The company is working on its main drug product, MNV-201, which is currently being tested for Pearson Syndrome and Myelodysplastic Syndrome [5] Recent Developments - Minovia has been awarded a $350,000 grant from Countdown for a Cure to develop novel mitochondrial blood-based biomarkers [1][2] - The grant will fund clinical operations for blood sample collection from approximately 30 patients with primary mitochondrial diseases and 140 samples from healthy controls [2] Research and Development - The company aims to develop blood-based functional mitochondrial biomarkers to identify patients who may benefit from its proprietary mitochondrial augmentation technology (MAT) [2] - A clinical trial has been initiated at Sheba Medical Center to collect blood samples for analysis and to determine a "MitoScore" for each sample [2] Market Need - Mitochondrial dysfunction is associated with rare genetic mitochondrial diseases and chronic age-related diseases, with a significant unmet need for effective treatments [3] - Currently, there are no approved therapies for mitochondrial dysfunction, nor functional tests to diagnose and quantify it [3] Business Combination - Minovia has entered into a definitive business combination agreement with Launch One Acquisition Corp., a publicly traded special purpose acquisition company [4] - The transaction is expected to close in late 2025, after which the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol [4]

LAUSANNE, Switzerland, Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET.A webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ...

Core Insights - Skye Bioscience, Inc. will host a virtual KOL event on September 4, 2025, to discuss the upcoming topline results from the Phase 2a CBeyond™ trial of nimacimab, a first-in-class peripheral CB1 antibody for obesity [1][2] - The event aims to provide clarity on what constitutes success in the proof-of-concept study, focusing on safety, tolerability, and new preclinical insights related to nimacimab [2][7] Company Overview - Skye Bioscience is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][8] - The company is conducting a Phase 2a clinical trial for nimacimab, which is designed to inhibit peripheral CB1 and is also assessing its combination with a GLP-1R agonist [8] KOL Event Highlights - The event will feature discussions with leading obesity experts, including Skye's CEO, Punit Dhillon, who will address the significance of safety and tolerability benchmarks in the obesity treatment landscape [2][7] - Key opinion leaders participating include Dr. Kevin Cannon, Dr. Sean Wharton, and Dr. Marcus Goncalves, who bring extensive experience in metabolic health and obesity research [3][4][6] Research Focus - The event will cover the mechanism and potential role of peripheral CB1 inhibition as a differentiated anti-obesity therapeutic pathway [7] - Newly generated preclinical data with nimacimab will be highlighted, contributing to the understanding of its potential advancement into Phase 2b development [2][7]

REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's CEO, Gil Efron will participate in a fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025. Details are as follows: H.C. Wainwright 27th Ann ...

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at 3:00 p.m. ET on September 8, 2025. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. About Seres TherapeuticsSeres Th ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Commercial Vehicle Group, Inc. (CVGI) manufactures and sells automotive components and assemblies. The Zacks Consensus Estimate for its current year earnings has been revised 116.7% downward over the last 60 days.First Internet Bancorp (INBK) is the bank holding company for First Internet Bank of Indiana. The Zacks Consensus Estimate for its current year earnings has been revised 38.5% downward over the last 60 days.MannKind Corporati ...